Skip to main content
Cureus logoLink to Cureus
. 2023 Jan 13;15(1):e33734. doi: 10.7759/cureus.33734

Effect of Obesity on Clinical Outcomes in COVID-19 Patients

Yahya Habis 1, Rahmah Alsilmi 1, Layal Alirbidi 2,✉, Maha Safhi 3, Fahad Alsallum 4, Roaa Alharbi 5, Abeer Samman 4
Editors: Alexander Muacevic, John R Adler
PMCID: PMC9922939  PMID: 36793811

Abstract

Background

Obesity is a well-known risk factor for developing severe coronavirus disease 2019 (COVID-19). In this study, we sought to determine the relationship between obesity and poor outcomes in patients with COVID-19 patients at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia.

Methods

We conducted a single-centered descriptive study of adult COVID-19 patients hospitalized between March 1 and December 31, 2020, at KAUH. Patients were classified according to body mass index (BMI) as overweight (BMI 25-29.9 kg/m2) or obese (BMI ≥30 kg/m2). The main outcomes were admission to the intensive care unit (ICU), intubation, and death.

Results

Data were analyzed from 300 COVID-19 patients. Most study participants were overweight (61.8%), and 38.2% were obese. The most significant comorbidities were diabetes (46.8%) and hypertension (41.9%). Both hospital mortality (10.4% for obese; 3.8% for overweight, p = 0.021) and intubation rates (34.6% for obese; 22.7% for overweight, p = 0.004) were significantly higher among obese patients than overweight patients. There was no significant difference in terms of ICU admission rate between both groups. However, intubation rates (34.6% for obese; 22.7% for overweight, p = 0.004) and hospital mortality (10.4% for obese; 3.8% for overweight, p = 0.021) were significantly higher among obese patients than overweight patients.

Conclusions

This study aimed to describe the effect of high BMI on the clinical outcome of COVID-19 patients in Saudi Arabia. Obesity is significantly correlated with poor clinical outcomes in COVID-19. It is also associated with higher mortality and the need for mechanical ventilation necessitating intensive care unit admission. Patients with higher BMI should be prioritized in the hospital setting, as they have a higher potential of developing severe COVID-19 complications and sequelae.

Keywords: infection, hospitalization, icu, covid-19, obesity

Introduction

The global coronavirus disease 2019 (COVID-19) pandemic was initially discovered in Wuhan, China, in December 2019 and resulted in a substantial pandemic associated with mortality and morbidities [1]. Comorbidities such as cancer, chronic obstructive pulmonary disease, chronic renal disease, history of solid organ transplant, cardiac problems, type 2 diabetes, and obesity can lead to poor clinical outcomes in the event of developing COVID-19 [2,3].

Obesity was associated with a significantly higher risk of severe pneumonia in hospitalized patients with COVID-19 [4]. According to meta-analysis data, the proportion of obese patients admitted to hospitals with COVID-19, and subsequent mortality increased substantially compared to non-obese patients [5]. Recent studies from numerous countries reported the severity of COVID-19 illness in obese people of varied racial and cultural backgrounds [6-9]. Studies have also shown that obese patients with COVID-19 are at risk of intensive care unit (ICU) admission and mechanical ventilation for respiratory support [10,11]. Obesity in Saudi Arabia has an estimated prevalence of 28.7% of the population [12]. We conducted this retrospective study to review the relationship between obesity and adverse outcomes in our institute and compare our results to previous studies. This study aimed to describe the effect of high body mass index (BMI) on the clinical outcome of patients with COVID-19 infection among Saudi patients.

Materials and methods

We conducted a single-centered, retrospective descriptive study at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. After calculating the sample size using the Raosoft sample size calculator (Raosoft, Inc, Seattle, WA). We included 300 obese and overweight COVID-19 patients, aged 18 or older who were admitted to KAUH between March 1 and December 31, 2020. The study excluded any patients younger than 18, pregnant, had a BMI < 25 kg/m2, received only outpatient care, or tested negative for COVID-19. Patient samples to confirm COVID-19 were collected from the upper respiratory tract using a nasopharyngeal swab or the lower respiratory tract by endotracheal aspirate. After acquiring the sample, the reverse transcription-polymerase chain reaction confirmed the diagnosis. We collected data using patient medical records with no contact or interaction with participants. The study was a noninterventional observational study involving a review of medical records, so the requirement for written informed consent was waived. The study was approved by the biomedical research unit of KAUH, Jeddah, Saudi Arabia (Reference No. 516-21).

Data collection method

We recorded patient demographic and anthropometric data and comorbidities. Patients were classified according to BMI as overweight (BMI 25-29.9 kg/m2) or obese (BMI > 30 kg/m2) according to World Health Organization guidelines [13]. The main outcomes were admission to the ICU, intubation, and death. Additional variables included length of hospital stay, re-admission, hospital-acquired infection (defined as having a positive culture during one admission period), re-intubation, noninvasive ventilation, and treatments (such as therapeutic anticoagulation, tocilizumab, corticosteroids, and plasma exchange).

Statistical analysis

The statistical analysis was performed using RStudio (R version 4.1.1). Descriptive statistics were used for categorical data (frequencies and percentages) and numerical data (means and standard deviation). The differences between BMI groups (overweight and obesity) were tested using a Chi-squared test or Fisher’s exact test for categorical variables. Factors associated with the primary outcomes were assessed by a univariate logistic regression analysis using the primary outcome variable as a dependent variable (intubation, ICU admission, or death) and the demographic variables and comorbidities as independent variables (each in a separate univariate model). In the instance of indicating multiple associations with the independent variables, we constructed a multivariate binary logistic regression model to assess the independent predictors of the outcome variables. Data were expressed as odds ratios (ORs) and 95% confidence intervals (95% CIs). Statistical significance was considered at p < 0.05.

Results

Demographic characteristics and clinical history of patients

Data were retrieved from 300 patients with a confirmed COVID-19 infection. Approximately two-thirds of them were males (63.3%) and patients aged ≥ 45 years represented 73.4% of the sample. Based on the BMI categories, less than half of the patients were obese (38.3%), whereas overweight patients represented 61.7% of the participants. The proportion of females in the obese group (49.6%) was significantly higher than those in the overweight group (28.6%, p < 0.001). Additionally, the proportion of obese patients among older adults was significantly higher than their overweight counterparts (44.3% vs 31.9%, p = 0.036) (Table 1).

Table 1. The association between demographic characteristics and BMI categories.

Abbreviation: BMI, body mass index.

Parameter Category Overall, N = 300 Overweight, N = 185 Obese, N = 115 p-value
Age 18 to <30 17 (5.7%) 15 (8.1%) 2 (1.7%) 0.036  
  30 to <45 63 (21.0%) 40 (21.6%) 23 (20.0%)
  45 to <60 110 (36.7%) 71 (38.4%) 39 (33.9%)
  60 or more 110 (36.7%) 59 (31.9%) 51 (44.3%)
Gender Male 190 (63.3%) 132 (71.4%) 58 (50.4%) <0.001  
  Female 110 (36.7%) 53 (28.6%) 57 (49.6%)

The most commonly reported comorbidities were diabetes mellitus (47.0%) and cardiovascular diseases (43.7%, Figure 1).

Figure 1. A bar chart depicting the percentages of comorbidities among patients under study.

Figure 1

Obesity was significantly associated with having a history of cardiovascular disease (54.8% among obese patients vs 36.8% among overweight, p = 0.002) and a history of chronic kidney disease (7.0% among obese patients vs 1.1% among overweight, p = 0.008, Table 2).

Table 2. The association between comorbidities and BMI categories.

*Immunocompromised: patients having a disease that is associated with a decrease/alteration of the immune system

Abbreviation: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; VTE, venous thromboembolism.

 

Parameter Overall, N = 300 Overweight, N= 185 Obese, N = 115 p-value
Cardiovascular disease 131 (43.7%) 68 (36.8%) 63 (54.8%) 0.002
Diabetes mellitus 141 (47.0%) 81 (43.8%) 60 (52.2%) 0.157
Chronic kidney disease 10 (3.3%) 2 (1.1%) 8 (7.0%) 0.008
Lung disease 16 (5.4%) 9 (4.9%) 7 (6.1%) 0.634
Chronic liver disease 2 (0.7%) 2 (1.1%) 0 (0.0%) 0.526
Malignancy 16 (5.3%) 11 (5.9%) 5 (4.3%) 0.549
Immunosuppression 14 (4.7%) 9 (4.9%) 5 (4.3%) 0.836

The association between hospital complications and both BMI categories

Regarding the characteristics of hospitalization, there were no significant differences between overweight and obese patients in terms of the rate of ICU admission. However, the proportion of obese patients who required intubation (11.6%) was significantly higher than those in the overweight group (2.7%, p = 0.002). Additionally, the proportion of dead patients in the obese group was significantly higher than their counterparts in the overweight groups (10.4% and 3.8%, respectively, p = 0.021, Table 3).

Table 3. The association between hospital complications and BMI categories.

*Variables were expressed as mean ± standard deviation; otherwise, frequencies and percentages were used to present variables.

Abbreviations: BMI, body mass index; ICU, Intensive Care Unit.

Characteristic Overall, n = 300, n (%) Overweight, n = 185, n (%) Obese, n = 115, n (%) p-value
ICU admission 52 (17.3%) 32 (17.3%) 20 (17.4%) 0.983
Intubation 18 (6.1%) 5 (2.7%) 13 (11.6%) 0.002
Death 19 (6.3%) 7 (3.8%) 12 (10.4%) 0.021

Factors associated with the primary outcomes

Results of the univariate regression analysis showed that intubation was significantly associated with being obese (OR = 4.7, 95% CI, 1.7 to 15.0, p = 0.004). Additionally, ICU admission was significantly higher among males compared to females (OR = 2.8, 95% CI, 1.4 to 6.2, p = 0.005, Table 4). 

Table 4. Results of the univariate regression analysis of the factors associated with intubation and ICU admission among patients under investigation.

NA: non-available computations because the variable had at least one zero frequency in one group.

OR: odds ratio; CI: confidence interval; ICU: intensive care unit

Parameter Category Intubation ICU admission
OR 95% CI p-value OR 95% CI p-value
Age 60 or more — —   — —  
  45 to <60 0.53 0.18, 1.45 0.227 0.84 0.43, 1.64 0.610
  30 to <45 0.14 0.01, 0.77 0.066 0.47 0.18, 1.13 0.107
  18 to <30 NA NA NA 0.5 0.08, 1.96 NA
Nationality Non-Saudi — —   — —  
  Saudi 0.84 0.26, 2.32 0.755 0.48 0.22, 0.97 0.053
Gender Female — —   — —  
  Male 0.9 0.34, 2.50 0.827 2.84 1.41, 6.22 0.005
BMI Group Overweight — —   — —  
  Obese 4.70 1.72, 15.0 0.004 1.01 0.54, 1.85 0.983
Cardiovascular disease No — —   — —  
Yes 1.30 0.49, 3.42 0.593 1.24 0.68, 2.26 0.481
Diabetes mellitus No — —   — —  
  Yes 0.71 0.26, 1.87 0.499 1.53 0.84, 2.82 0.165
Chronic kidney disease No — —   — —  
Yes 1.99 0.10, 11.8 0.529 2.11 0.44, 7.87 0.292
Lung disease No — —   — —  
  Yes 1.11 0.06, 6.03 0.925 0.67 0.10, 2.48 0.598
Chronic liver disease No — —   — —  
Yes NA NA NA NA NA NA
Malignancy No — —   — —  
  Yes 2.36 0.35, 9.45 0.283 0.67 0.10, 2.49 0.602
Immunosuppression No — —   — —  
  Yes 1.20 0.06, 6.59 0.865 0.35 0.02, 1.84 0.323

Since only one variable was significantly associated with intubation and ICU admission (one variable for each outcome), constructing a multivariate regression analysis for these outcomes was not applicable. Concerning the factors associated with death, results revealed that death was significantly lower among participants aged 45 to <60 compared to those aged 60 years or older (OR = 0.3, 95% CI, 0.1 to 0.9, p = 0.038). Furthermore, death was significantly higher among obese patients (OR = 3.0, 95% CI, 1.2 to 8.2, p = 0.027), as well as those who were admitted to the ICU (OR = 6.0, 95% CI, 1.6 to 8.0, p < 0.001) and intubated (OR = 5.3, 95% CI, 1.7 to 18.3, p < 0.001) (Table 5). 

Table 5. Results of the univariate and multivariate regression analysis of the factors associated with death among patients under investigation.

NA: non-available computations because the variable had at least one zero frequency in one group.

OR: odds ratio; CI: confidence interval; ICU: intensive care unit

Parameter Category Univariate Multivariate
OR 95% CI p-value OR 95% CI p-value
Age 60 or more — —   — —  
  18 to <30 NA NA NA NA NA NA
  30 to <45 NA NA NA NA NA NA
  45 to <60 0.33 0.10, 0.89 0.038 0.32 0.07, 1.29 0.119
Nationality Non-Saudi — —        
  Saudi 0.8 0.25, 2.15 0.671      
Gender Female — —        
  Male 0.62 0.24, 1.62 0.321      
BMI Group Overweight — —   — —  
  Obese 2.96 1.15, 8.18 0.027 3.69 0.84, 17.10 0.084
Cardiovascular disease No — —        
  Yes 2.33 0.91, 6.44 0.084      
Diabetes mellitus No — —        
  Yes 1.6 0.63, 4.24 0.329      
Chronic kidney disease No — —        
Yes 1.68 0.09, 9.69 0.632      
Lung disease No — —        
  Yes 0.98 0.05, 5.29 0.986      
Chronic liver disease No — —        
Yes NA NA 0.990      
Malignancy No — —        
  Yes 3.87 0.83, 13.60 0.050      
Immunosuppression No — —        
  Yes 1.15 0.06, 6.27 0.899      
Intubation No — —   — —  
  Yes 5.30 1.69, 18.30 <0.001 4.61 0.97, 23.0 0.054
ICU admission No — —   — —  
  Yes 5.97 1.62, 18.70 <0.001 4.85 1.25, 8.00 <0.001

The significantly associated variables were exclusively entered in a multivariate model to account for the independent association between the variables and the risk of death. To fulfill the assumptions of logistic regression, we assessed the risk of multicollinearity using the variance inflation factor (VIF), and we found no risk of multicollinearity (VIF < 5 for all independent variables). Additionally, we excluded one record which was deemed an influential outlier (with the absolute standardized error of >3, Figure 2).

Figure 2. A scatterplot of the standardized residuals of individual data to assess the potential influential data points.

Figure 2

 In the final mode, the independent variables explained 59.8% of the variance in the risk of death. Only ICU admission was an antecedent risk factor for death among patients (OR = 4.9, 95% CI, 1.3 to 8.0, p < 0.001, Table 5).

Discussion

It is well established that obesity is a clinically important risk factor for severe COVID-19 leading to pneumonia or acute respiratory distress syndrome requiring intubation. Our objective was to investigate the impact of obesity on patients with COVID-19 who required hospitalization, a population particularly vulnerable to serious medical complications [14]. Our results were consistent with several previous reports showing that higher BMI is significantly associated with more severe COVID-19 disease, necessitating hospitalization [15,16].

An earlier study investigating obesity as a risk factor for severe COVID-19 reported that obese patients have altered immune cell activity compared to healthy-weight patients; this alteration of the host defense mechanism puts patients at increased risk of COVID-19 complications [17]. Moreover, a reservoir for viral replication and, therefore, increased viral shedding-can be found in the adipose tissue in obese patients, making them subsequently more susceptible to severe disease courses [18].

Obese patients also have a higher risk of respiratory failure than non-obese patients [19]. Our findings are consistent with previous reports that evaluated the impact of high BMI in hospitalized patients with COVID-19 [20-23]. Our results indicated that the higher the BMI, the higher the risk of intubation, as obese patients required intubation more than overweight patients. This finding could be attributed to a significant decrease in protective cardiopulmonary reserves in obese patients due to adaptation mechanisms in the respiratory system that cause an increase in airway resistance and reduce gas exchange. Further complicating matters, obese patients with COVID-19 have increased immune dysregulation and dysfunction that increase the risk of pneumonia and progression to critical illness and multiorgan failure [24,25].

Furthermore, our study demonstrates that being obese puts the patient at increased risk of death from COVID-19, as it showed that more obese patients died than overweight patients. As previously reported in several cohort studies, obesity is associated with several remarkable comorbidities, such as diabetes, hypertension, heart disease, and kidney disease. However, the mortality estimate in obese patients is directly proportional to the increase in BMI [26,27], which aligns with our results.

This study had some limitations. It included many patients from our institute; however, it is retrospective. Also, data of the included patients were collected before the era of COVID-19 vaccination; therefore, it may not reflect the change in the epidemic noted upon the introduction of the COVID-19 vaccine. Moreover, this study reflects a single-center outcome; the findings cannot be generalized to other Saudi Arabia regions. However, our results are consistent with prior reports from international studies.

Conclusions

This study aimed to describe the effect of high BMI on the clinical outcome of COVID-19 patients in Saudi Arabia. According to our results, obesity is a significant predictor of the progression of COVID-19 infection to severe pneumonia necessitating mechanical ventilation and death. Clinicians should give special attention to obese COVID-19 patients to improve their survival and disease outcomes.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study. Institutional Review Board of King Abdulaziz University issued approval 516-21

Animal Ethics

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

References

  • 1.Johns Hopkins University CRC. Coronavirus resource center. COVID-19 United States Cases by County. [ Dec; 2022 ]. 2020. https://coronavirus.jhu.edu/us-map https://coronavirus.jhu.edu/us-map
  • 2.Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Petrilli CM, Jones SA, Yang J, et al. BMJ. 2020;369:0. doi: 10.1136/bmj.m1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. Suleyman G, Fadel RA, Malette KM, et al. JAMA Netw Open. 2020;3:0. doi: 10.1001/jamanetworkopen.2020.12270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Cai Q, Chen F, Wang T, et al. Diabetes Care. 2020;43:1392–1398. doi: 10.2337/dc20-0576. [DOI] [PubMed] [Google Scholar]
  • 5.Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Popkin BM, Du S, Green WD, et al. Obes Rev. 2020;21:0. doi: 10.1111/obr.13128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Recalde M, Roel E, Pistillo A, et al. Int J Obes (Lond) 2021;45:2347–2357. doi: 10.1038/s41366-021-00893-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID- 19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Hendren NS, de Lemos JA, Ayers C, et al. Circulation. 2021;143:135–144. doi: 10.1161/CIRCULATIONAHA.120.051936. [DOI] [PubMed] [Google Scholar]
  • 8.The association between obesity and severity in patients with coronavirus disease 2019: a retrospective, single-center study, Wuhan. Zhang J, Xu Y, Shen B, et al. Int J Med Sci. 2021;18:1768–1777. doi: 10.7150/ijms.54655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Association between obesity and diabetes prevalence and COVID-19 mortality in Mexico: an ecological study. Noyola DE, Hermosillo-Arredondo N, Ramírez-Juárez C, Werge-Sánchez A. J Infect Dev Ctries. 2021;15:1396–1403. doi: 10.3855/jidc.15075. [DOI] [PubMed] [Google Scholar]
  • 10.High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Simonnet A, Chetboun M, Poissy J, et al. Obesity (Silver Spring) 2020;28:1195–1199. doi: 10.1002/oby.22831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.BMI is associated with coronavirus disease 2019 intensive care unit admission in African Americans. Alkhatib AL, Kreniske J, Zifodya JS, et al. Obesity (Silver Spring) 2020;28:1798–1801. doi: 10.1002/oby.22937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.A review of prevalence of obesity in Saudi Arabia. Alqarni SSM. https://t.ly/qYQS J Obes Eat Disord. 2016;2:1–6. [Google Scholar]
  • 13.Obesity: preventing and managing the global epidemic. Report of a WHO consultation. https://pubmed.ncbi.nlm.nih.gov/11234459/ World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. [PubMed] [Google Scholar]
  • 14.Medical complications of obesity: heightened importance in a COVID era. Prendergast H, Tyo C, Colbert C, Kelley M, Pobee R. Int J Emerg Med. 2022;15:29. doi: 10.1186/s12245-022-00431-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Impact of obesity on COVID-19 patients. Yu W, Rohli KE, Yang S, Jia P. J Diabetes Complications. 2021;35:107817. doi: 10.1016/j.jdiacomp.2020.107817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. Clin Infect Dis. 2020;71:896–897. doi: 10.1093/cid/ciaa415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.The impact of obesity on hospitalized patients with COVID-19 infection in the Eastern Province of Saudi Arabia. AlKhafaji D, Al Argan R, Albahrani S, et al. J Med Life. 2022;15:425–432. doi: 10.25122/jml-2022-0033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Belančić A, Kresović A, Rački V. Obes Med. 2020;19:100259. doi: 10.1016/j.obmed.2020.100259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Obesity and the risk of intubation or death in patients with coronavirus disease 2019. Frank RC, Mendez SR, Stevenson EK, Guseh JS, Chung M, Silverman MG. Crit Care Med. 2020;48:0–101. doi: 10.1097/CCM.0000000000004553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection. Saito T, Yamaguchi T, Kuroda S, et al. J Cardiol. 2022;79:476–481. doi: 10.1016/j.jjcc.2021.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, Jebb SA. Lancet Diabetes Endocrinol. 2021;9:350–359. doi: 10.1016/S2213-8587(21)00089-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Body mass index and risk for intubation or death in SARS-CoV-2 infection. Sanchis-Gomar F, Lavie CJ, Sharma A, Henry BM, Lippi G. Ann Intern Med. 2021;174:885–886. doi: 10.7326/L21-0014. [DOI] [PubMed] [Google Scholar]
  • 23.Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Anderson MR, Geleris J, Anderson DR, et al. Ann Intern Med. 2020;173:782–790. doi: 10.7326/M20-3214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Impact of obesity and metabolic syndrome on immunity. Andersen CJ, Murphy KE, Fernandez ML. Adv Nutr. 2016;7:66–75. doi: 10.3945/an.115.010207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Sattar N, McInnes IB, McMurray JJ. Circulation. 2020;142:4–6. doi: 10.1161/CIRCULATIONAHA.120.047659. [DOI] [PubMed] [Google Scholar]
  • 26.Association between body-mass index and risk of death in more than 1 million Asians. Zheng W, McLerran DF, Rolland B, et al. N Engl J Med. 2011;364:719–729. doi: 10.1056/NEJMoa1010679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Body mass index at various ages and mortality in Chinese women: impact of potential methodological biases. Zhang X, Shu XO, Chow WH, et al. Int J Obes (Lond) 2008;32:1130–1136. doi: 10.1038/ijo.2008.63. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES